0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biostar Pharmaceuticals
Its shares trade under the ticker BSPM. It has been listed since 9 July 2008. In the fiscal year to 31 December 2016, it reported revenue of $2.4m and a net loss of $5.7m. At that date it held total assets of $42.5m and shareholders' equity of $36.9m.
BioStar Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of pharmaceutical and health supplement products for a variety of diseases and conditions. The company is headquartered in Xianyang, Shaanxi. The company went IPO on 2008-07-09. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People's Republic of China (PRC or China). The firm offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The firm's products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The firm's products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Jul 2008
- Employees
- 438
Leadership
Pay as last reported
- Ronghua WangChairman of the Board, President, Chief Executive Officer, since 2007$17,573
- Ms. Xiaojuan ZhaiChief Financial Officer
- Zhenghong WangChief Operating Officer$6,586
- Shuang GongSecretary of Board
- Ms. Melissa Fan ChenIndependent Director
- Ms. Huiping LiaoIndependent Director
- Haipeng WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biostar Pharmaceuticals Inc has a diverse and comprehensive product portfolio that includes a range of pharmaceuticals and medical products. This allows the company to cater to different market segments and increase its revenue streams.
- Biostar Pharmaceuticals Inc has built a strong brand reputation over the years, known for its quality products and commitment to customer satisfaction. This has helped the company gain customer loyalty and trust in the market.
- The company has established a wide distribution network, allowing its products to reach a large number of customers across various markets. This gives Biostar Pharmaceuticals Inc a competitive edge over its peers and facilitates efficient supply chain management.
Weaknesses
- Biostar Pharmaceuticals Inc primarily operates in a specific geographic region, limiting its market reach and growth opportunities. This geographical dependency can expose the company to risks such as economic downturns or regulatory changes in that area.
- The company's research and development efforts for new and innovative products have been relatively limited. This could hinder Biostar Pharmaceuticals Inc's ability to stay competitive in the rapidly evolving pharmaceutical industry.
Opportunities
- Biostar Pharmaceuticals Inc has the opportunity to enter and expand its presence in emerging markets, where there is growing demand for pharmaceutical products. This can lead to increased revenue and market share for the company.
- By allocating resources towards research and development, Biostar Pharmaceuticals Inc can enhance its product pipeline and introduce innovative medicines or treatments. This can open up new market opportunities and give the company a competitive advantage.
Threats
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Biostar Pharmaceuticals Inc faces the threat of intense competition from both established pharmaceutical companies and emerging players.
- The pharmaceutical industry is subject to strict regulations and compliance requirements. Changes in regulations or failure to comply with existing regulations can pose significant challenges for Biostar Pharmaceuticals Inc and impact its operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.